Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portland's primary knee replacement:

This article was originally published in Clinica

Executive Summary

Australia's Portland Orthopaedics has received US FDA 510(k) clearance to sell its primary knee replacement, Beacon. The device, licensed from US firm Signal Medical, is for use as a first-time knee replacement. The Sydney-based firm plans to use the product as a manufacturing platform, together with a Aus$1.9m (US$1.4) Industry grant, to develop a revision knee. The revision knee, designed for people with poor bone quality who need a greater modularity and fixing capability, will be a "higher margin product with distinct points of difference in the market", said Portland, which expects CE-marking of Beacon the product to be "imminent".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel